节拍化疗的抗肿瘤机制及其在晚期非小细胞肺癌治疗中的应用  

The mechanisms underlying metronomic chemotherapy and its application in advanced non-small cell lung cancer

作　　者：王雪 李琳 Wang Xue;Li Lin(Peking University Fifth School of Clinical Medicine,Beijing 100730,China;Department of Medical Oncology,Beijing Hospital,National Center of Gerontology Institute of Geriatric Medicine,Chinese Academy of Medical Sciences,Peking University Fifth School of Clinical Medicine,Beijing 100730,China)

机构地区：[1]北京大学第五临床医学院,北京100730 [2]北京医院肿瘤内科、国家老年医学中心、中国医学科学院老年医学研究所,北京100730

出　　处：《中华老年医学杂志》2023年第5期614-620,共7页Chinese Journal of Geriatrics

基　　金：中国医学科学院医学与健康科技创新工程项目(2021-12M-1-012)。

摘　　要：非小细胞肺癌(NSCLC)的发病率和死亡率均位于恶性肿瘤的前列。节拍化疗的抗肿瘤机制主要为抑制肿瘤血管生成、调节免疫微环境和针对肿瘤细胞自身等。作为传统化疗的替代方案,节拍化疗在晚期NSCLC的治疗中展现出良好前景,多个临床试验探索了节拍化疗在晚期NSCLC治疗中的应用,方案包括单药或与化疗、抗血管生成治疗、靶向治疗及免疫治疗等的联合使用。现对节拍化疗的抗肿瘤作用机制及其在晚期NSCLC治疗中的临床应用进行综述,为NSCLC治疗方案的优化提供更多证据。The morbidity and mortality of non-small cell lung cancer(NSCLC)are among the highest of all malignancies.The mechanisms concerning metronomic chemotherapy include anti-angiogenesis,immune microenvironment regulation,and cytotoxic effects,among others.As an alternative to traditional chemotherapy,metronomic chemotherapy has shown promising outcomes in the treatment of advanced NSCLC.Several clinical trials have explored the application of metronomic chemotherapy in the treatment of advanced NSCLC,either as a monotherapy or in combination with chemotherapy,anti-angiogenic therapy,targeted therapy or immunotherapy.This paper mainly reviews the mechanisms underlying metronomic chemotherapy and its clinical application in advanced NSCLC,in order to provide more evidence for the optimization of NSCLC treatment regimens.

关 键 词：癌 非小细胞肺 节拍化疗 

分 类 号：R734.2[医药卫生—肿瘤]